Oncology
Cancer clinical trials
Studies of cancers and tumors of every type and site, from prevention to treatment. We’re tracking 20,151 recruiting studies in this area right now.
By phase
- Not applicable9,506
- Phase 24,400
- Phase 12,662
- Phase 1/Phase 21,649
- Phase 31,391
- Phase 2/Phase 3283
- Phase 4260
Top conditions
- Breast Cancer1,197
- Prostate Cancer647
- Cancer634
- Colorectal Cancer480
- Lung Cancer416
- Ovarian Cancer336
- Multiple Myeloma328
- Pancreatic Cancer288
- Gastric Cancer283
- Acute Myeloid Leukemia279
- Hepatocellular Carcinoma256
- Solid Tumor245
- Advanced Solid Tumor235
- Head and Neck Cancer225
- Cervical Cancer223
- Endometrial Cancer207
- Advanced Solid Tumors201
- Esophageal Cancer191
Leading sponsors
- M.D. Anderson Cancer Center453
- Fudan University302
- National Cancer Institute (NCI)292
- Memorial Sloan Kettering Cancer Center288
- Sun Yat-sen University273
- Mayo Clinic238
- City of Hope Medical Center141
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences140
- AstraZeneca133
- Second Affiliated Hospital, Zhejiang University, School of Medicine128
Where studies are running
- California1,408
- Texas635
- Arizona512
- Florida434
- Alabama427
- New York405
- Massachusetts342
- Maryland330
- New Jersey269
- Pennsylvania234
Recruiting studies20,151 total
- NCT06682936Recruiting
Outpatient talc procedure for cancer-related fluid buildup
This trial tests whether a talc procedure to seal the lung (pleurodesis) can be done safely in an outpatient setting for people with fluid buildup from cancer. It aims to make the treatment more convenient.
Stockton-on-Tees, County DurhamAges 18 years+ - NCT06683885RecruitingPhase 1/Phase 2
Targeted drug combo for elderly DLBCL patients
This trial tests a combination of targeted drugs (Obutinib or Decitabine) with standard chemo (Rituximab, Cyclophosphamide, Prednisone) for elderly patients with newly diagnosed diffuse large B-cell lymphoma who cannot handle full-dose chemotherapy. The goal is to see if this approach is safer and works as well.
Zhengzhou, HenanAges 65 years+ - NCT06684600RecruitingPhase 2
Treating advanced esophageal cancer with dalpiciclib and pyrotinib
This trial tests a combination of two targeted drugs (dalpiciclib and pyrotinib) for people with advanced esophageal squamous cell carcinoma whose cancer has gotten worse during or after first chemotherapy. The goal is to see if this drug pair can help shrink tumors or slow the disease.
Beijing, Beijing MunicipalityAges 18–75 - NCT07654400RecruitingPhase 2
Study of BL-M14D1 plus Atezolizumab for advanced small cell lung cancer
This trial tests a new drug combination (BL-M14D1 and Atezolizumab) for people with extensive-stage small cell lung cancer that has not responded to standard treatments. The goal is to see if the combination can shrink tumors or slow the growth of the cancer.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07647510RecruitingPhase 3
Testing Claseprubart for Generalized Myasthenia Gravis
This study tests whether a new drug called claseprubart can help adults with generalized myasthenia gravis (a condition where muscles get weak and tired easily). The drug works by targeting part of the immune system that damages muscles.
Pasadena, CaliforniaAges 18–80 - NCT07648472RecruitingPhase 1
Safety and efficacy of OVV-01 injection for advanced solid tumors
This study tests a new cancer treatment called OVV-01 that is injected directly into tumors or given through the vein. It's for patients with advanced solid cancers (like melanoma, lung, breast, or colon cancer) who have already tried at least two standard treatments without success.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07649122RecruitingPhase 3
PET Scan Imaging for Prostate Cancer Recurrence Detection
This study tests a new type of PET scan (a detailed imaging test) to find out if prostate cancer has come back after treatment. You'll receive an injection of a special tracer and then have a scan that takes pictures to help doctors locate any cancer.
Nanjing, JiangsuAges 18 years+ - NCT07652281RecruitingPhase 1
Study of SHR-5421 for multiple myeloma
This trial tests a new drug, SHR-5421, for people with multiple myeloma that has come back or stopped responding to treatment. It aims to see if the drug is safe and how well it works.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07650773Recruiting
Understanding liver cancer care patterns and outcomes
This study reviews medical records of people diagnosed with hepatocellular carcinoma (liver cancer) between 2015 and 2023 to better understand how the disease progresses and how different treatments work. Your information helps researchers learn what care approaches work best for future patients.
Al MansurahAges Any age - NCT07646782Recruiting
Human Observatory Study: Aging and Longevity Research
This study observes how people age over time to better understand what helps people live longer and healthier lives. You'll share health information through surveys or online screening, and researchers will track changes in your health and wellbeing.
Boulder, ColoradoAges 18 years+ - NCT07647744RecruitingPhase 1
CD70-Targeted Cell Therapy for Advanced Kidney Cancer
This study tests a new cell-based treatment designed to target kidney cancer cells that have a protein called CD70. The treatment involves collecting your immune cells, modifying them in the lab, and infusing them back to fight the cancer. It's for patients with advanced kidney cancer who have already tried at least one standard immunotherapy.
ShanghaiAges 18–70 - NCT07653685RecruitingPhase 1/Phase 2
Study of a new drug with chemotherapy for advanced colorectal cancer
This trial tests a new drug (TQB2930) combined with chemotherapy, with or without another drug called bevacizumab, for people whose colorectal cancer has spread or cannot be removed by surgery and has a specific protein called HER2. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
Beijing, Beijing MunicipalityAges 18–75 - NCT07648914RecruitingPhase 3
BL-B01D1 versus chemotherapy for advanced hormone-receptor-positive breast cancer
This trial tests a new targeted drug called BL-B01D1 against standard chemotherapy in patients with advanced breast cancer that is hormone-receptor-positive (HR+) and HER2-negative, and has stopped responding to hormone treatments. The goal is to see if the new drug works better or has fewer side effects.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07647328RecruitingPhase 3
Camizestrant and ribociclib for advanced hormone-receptor-positive breast cancer
This trial tests a combination of two drugs (camizestrant and ribociclib) for advanced breast cancer that is hormone-receptor-positive and HER2-negative. The study aims to see if this combination helps patients whose cancer cannot be surgically removed or treated with radiation alone.
Duarte, CaliforniaAges 18–130 - NCT07646626RecruitingPhase 2
New antibody drugs for advanced HER2-positive cancers
This trial tests two new antibody drugs (SSGJ-705 and SSGJ-612), alone or combined with chemotherapy, in patients with advanced cancers that have a protein called HER2. The study aims to see if this combination can shrink tumors and help patients live longer.
Hangzhou, ZhejiangAges 18–75 - NCT07652242RecruitingPhase 1
A RNA vaccine for stage 2-3 triple negative breast cancer
This trial tests an experimental RNA vaccine (ITI-5000) designed to help your immune system fight triple-negative breast cancer. It is for people with stage 2 or 3 disease who have already had some cancer treatment.
Grand Rapids, MichiganAges 18 years+ - NCT07651878RecruitingPhase 1
Vididencel immunotherapy for chronic myeloid leukemia with minimal residual disease
This study tests whether an experimental immune therapy called vididencel can help patients with chronic myeloid leukemia (CML) who have responded partially to standard tyrosine kinase inhibitor (TKI) drugs. The goal is to see if this therapy can further reduce the cancer cells remaining in their body.
BergenAges 18 years+ - NCT07648030RecruitingPhase 2
Rusfertide for polycythemia vera in Japanese adults
This study tests a new medicine called rusfertide for polycythemia vera (PV)—a blood condition where your body makes too many red blood cells. The trial aims to see if rusfertide can help reduce the need for blood removal procedures (phlebotomy) that PV patients currently need to manage their condition.
Nagoya, Aichi-kenAges 18 years+ - NCT07648264RecruitingPhase 3
Immune Boost Treatment After CAR-T or TCE Therapy
This study tests a new immunoglobulin (antibody) treatment called IgPro20 in adults whose immune systems became weakened after receiving CAR-T cell or TCE therapies for blood cancers. The goal is to help strengthen your immune system and reduce infection risk.
Orange, CaliforniaAges 18 years+ - NCT06682156Recruiting
Switching to carfilzomib for multiple myeloma patients who can't tolerate bortezomib
This trial is for people newly diagnosed with multiple myeloma who are having side effects from their first treatment with bortezomib. It tests switching to a different drug called carfilzomib to see if it works well with fewer side effects.
Suzhou, JiangsuAges 18 years+ - NCT06685562Recruiting
Testing a map to help make cancer decisions together
This study tests a new way to help people with cancer and their doctors make decisions together. If you have prostate, breast, or melanoma cancer, this trial may help you understand your options better.
VejleAges 18 years+ - NCT06380686Recruiting
Head and neck cancer research platform
This trial is collecting information and blood samples from people with head and neck cancer that cannot be cured. It aims to learn more about the cancer and find better ways to treat it.
EssenAges 18 years+ - NCT07650240RecruitingPhase 2
PSMA Therapy and Hormone Treatment for Early-Stage Prostate Cancer Spread
This trial tests a combination of two treatments for men with prostate cancer that has spread to a small number of sites: a radioactive injection (177Lu-PSMA-617) that targets cancer cells, plus hormone-blocking medication. The goal is to control the cancer and delay progression.
Rochester, MinnesotaAges 18 years+ - NCT07654426RecruitingPhase 2
Heart protection during lymphoma chemotherapy
This trial tests if a heart-protecting drug (dexrazoxane) can prevent heart damage in people getting chemotherapy for certain types of large B-cell lymphoma. It is for patients who already have heart risk factors or a history of heart failure.
Boston, MassachusettsAges 18 years+
Common questions
- How many cancer clinical trials are recruiting?
- Clin2 is tracking 20,151 recruiting oncology studies from the U.S. registry right now, out of 30,040 we cover in this area in total.
- What does “Cancer” cover here?
- Studies of cancers and tumors of every type and site, from prevention to treatment. We group each study into cancer based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a cancer trial near me?
- Use the search to filter cancer studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
- Brain & nervous system
- Heart & circulation
- Hormones & metabolism
- Mental health
- Digestive system
- Lungs & breathing
- Immune system & allergy
- Women’s health & pregnancy
- Skin
- Blood & lymphatic
- Kidney & urinary
- Infections
- Genetic & congenital
- Bones, joints & muscles
- Pain
- Injuries & trauma
- Mouth & dental
- Eyes & vision
- Ear, nose & throat
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.